TapImmune Inc. is a biotechnology company. The Company is focused on immunotherapy engaged in the development of peptide and gene-based immunotherapeutic and vaccines for the treatment of cancer and infectious disease. The Company's technologies include peptide antigen technologies and deoxyribonucleic acid (DNA) expression technologies, Polystart and TAP. The Company is focused on the clinical development and testing of its product candidates. The Company has two Phase I studies concluded at the Mayo Clinic, which are designed to evaluate the safety and immune response(s) of a set of HER2/neu antigens for a HER2/neu breast cancer vaccine and Folate Receptor Alpha for triple negative breast and ovarian cancer respectively. The Company is conducting preclinical studies for Polystart.